Podcast: Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic...
JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, “Digital Pa [...]
Development and Validation of an Artificial Intelligence Digital Pathology...
Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receivin [...]
The Future of AI in Urology
Artificial intelligence (AI) has become a disruptor in nearly every sector, including health care. In a recent interview with [...]
Precision Medicine for Prostate Cancer — AI can help...
The multimodal ArteraAI Prostate Testopens in a new tab or window (AI Test) is currently the only test that provides insights [...]
An Artificial Intelligence–Digital Pathology Algorithm Predicts Survival After Radical...
Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (R [...]
Validation of a Digital Pathology–Based Multimodal Artificial Intelligence Biomarker...
A multimodal artificial intelligence (MMAI) biomarker was developed using clinical trial data from North American men with lo [...]
Diagnexia and Artera Partner to Bring Groundbreaking AI Prostate...
Diagnexia, the UK’s leading provider of AI-powered digital pathology diagnostic services, is thrilled to announce an exclusiv [...]
The 4 step process to achieve AI data locality...
As part of Artera’s mission to improve patient outcomes globally, Artera launched a highly successful product for patients wi [...]